Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Amgen wins EU green light for first virus-based cancer drug

A first-in-class drug from Amgen based on a tumor-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of months.   The decision is a further milestone for a technology that has long fascinated scientists but has previously proved difficult to harness. The European […]

Read More »

Spectrum says FDA declines to approve Evomela for injection

Biotechnology company Spectrum Pharmaceuticals Inc said the U.S. Food and Drug Administration declined to approve its Evomela injection to treat patients with multiple myeloma, a form of blood cancer that arises from plasma cells found in bone marrow. Spectrum Pharmaceuticals said it received a complete response letter, which the FDA sends to let a drug […]

Read More »

Lack of sleep linked to risk factors for diabetes and heart disease

(Reuters Health) – People who get less than six hours of sleep a night may be more likely to have risk factors that increase their odds of diabetes, heart disease and strokes, a Korean study suggests. This combination of risk factors – including high blood sugar, high cholesterol, extra fat around the midsection, high blood […]

Read More »

FDA clears Merrimack’s pancreatic cancer drug with warning

The U.S. Food and Drug Administration on Thursday approved Merrimack Pharmaceutical Inc’s pancreatic cancer drug, Onivyde, with a severe safety warning. The company’s shares fell as much as 28 percent to a 13-month low of $7.27 in afternoon trade before halving the losses. Onivyde, in combination with chemotherapy treatments 5-fluorouracil and leucovorin, aims to treat […]

Read More »

Aurobindo Receives FDA Approval for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg

Dayton, N.J., October 22, 2015 – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Memantine Hydrochloride Tablets USP, 5 mg and 10 mg to be bioequivalent and, therefore, therapeutically equivalent […]

Read More »

Orchestrated customer engagement: Going beyond multichannel marketing

IMS Health has released its report Orchestrated Customer Engagement, which looks at what pharma companies need to do beyond multichannel and omnichannel marketing in order to deliver a full customer engagement experience. Med Ad News spoke with Richie Etwaru, chief digital officer of IMS Health and primary author of the report, to expand on some […]

Read More »

Perrigo to Chop 800 Jobs, Buy Back Shares to Fend Off Mylan

Dublin, Ireland-based Perrigo Company plc (PRGO) announced today that it will take a number of actions, including layoffs, to increase profitability and help fend off a hostile takeover by Canonsburg, Penn. and UK-based Mylan N.V.   The company plans to consolidate its global supply chain, operations and procurement management activities into a single global center […]

Read More »

British PM Cameron against imposing sugar tax to fight child obesity

British Prime Minister David Cameron is against imposing a tax on sugar as a means to tackle childhood obesity, his spokesman said on Thursday, rejecting the arguments of a high-profile campaign for a levy on sugary food and drinks.   Childhood obesity is described as one of the most serious public health challenges of the […]

Read More »

ImmunoGen, Roche gastric cancer drug fails study

ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study. ImmunoGen entered into a royalty purchase agreement with Roche for Kadcyla this year. Kadcyla, approved in 2013 for the treatment of late-stage breast cancer, was being tested as a second-line treatment […]

Read More »

Gilead’s new HIV drug shows lower side-effects over longer term

Drugmaker Gilead Sciences Inc said data from a late-stage study showed that its experimental drug, Genvoya, showed reduced side-effects compared with an older version of the drug in treating HIV-infected patients over a longer term. The company said Genvoya was as good as Stribild, which is the older version, after 96 weeks of treatment and […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom